Profile data is unavailable for this security.
About the company
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-60.18m
- Incorporated2021
- Employees14.00
- LocationZura Bio Ltd4225 Executive Square, Suite - 600SAN DIEGO 92037United StatesUSA
- Phone+1 (858) 247-0520
- Websitehttps://zurabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ESSA Pharma Inc | 0.00 | -27.73m | 212.06m | 50.00 | -- | 1.59 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Fractyl Health Inc | 148.00k | -83.16m | 214.10m | 102.00 | -- | 2.54 | -- | 1,446.62 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
Rezolute Inc | 0.00 | -58.21m | 214.27m | 51.00 | -- | 2.36 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 215.84m | 122.00 | -- | 2.06 | -- | 301.00 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 216.82m | 49.00 | -- | 4.88 | -- | 2,676.83 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Zura Bio Ltd | 0.00 | -60.18m | 223.53m | 14.00 | -- | 2.51 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Omeros Corp | 0.00 | -179.09m | 224.82m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Mersana Therapeutics Inc | 38.30m | -134.81m | 225.14m | 123.00 | -- | 8.05 | -- | 5.88 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 225.46m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -124.58m | 228.49m | 140.00 | -- | 1.44 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Solid Biosciences Inc | 0.00 | -90.25m | 229.13m | 88.00 | -- | 1.07 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 231.11m | 13.00 | 1.89 | 0.6603 | 7.55 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 233.01m | 135.00 | -- | 8.72 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Renovaro Inc | 0.00 | -53.93m | 233.06m | 11.00 | -- | 1.38 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Sutro Biopharma Inc | 154.07m | -114.96m | 235.57m | 300.00 | -- | 1.84 | -- | 1.53 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Holder | Shares | % Held |
---|---|---|
Athanor Capital LPas of 25 Mar 2024 | 4.80m | 7.54% |
Deep Track Capital LPas of 18 Apr 2024 | 3.33m | 5.23% |
RA Capital Management LPas of 22 Apr 2024 | 3.22m | 5.05% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 2.85m | 4.48% |
Great Point Partners LLCas of 31 Mar 2024 | 2.76m | 4.33% |
Armistice Capital LLCas of 31 Mar 2024 | 1.65m | 2.59% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 993.22k | 1.56% |
Citadel Advisors LLCas of 31 Mar 2024 | 681.10k | 1.07% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 559.97k | 0.88% |
Geode Capital Management LLCas of 31 Mar 2024 | 487.13k | 0.77% |